A recent FDA warning letter shows what separates a defensible letter to file from a thin one. The difference is the design change assessment behind it, and how well it connects to complaints and CAPA.
A New Statutory Attempt at LDT Oversight
HR 8890 would keep LDT oversight with CMS under CLIA and add a public validation database, serious harm reporting, and optional third-party review.